Representation of Check-Cap Ltd. in $35M Registered Direct Offering
Represented of Check-Cap Ltd. in a $35 million registered direct offering of ordinary shares and warrants.
H.C. Wainwright & Co., LLC served as exclusive placement agent for the offering.
Check-Cap, listed on NASDAQ, is a clinical stage medical diagnostics company aiming to redefine colorectal cancer (CRC) screening through the introduction of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer and enable early intervention and cancer prevention. C-Scan uses an ultra-low dose X-ray capsule, an integrated positioning, control and recording system, as well as proprietary software to generate a 3D map of the inner lining of the colon as it travels naturally along the gastrointestinal tract. C-Scan is non-invasive and requires no sedation. Unlike other capsule technologies, it requires no bowel preparation, allowing the patients to continue their daily routine with no interruption.
Search by
Clear Search